cGAS-STING inhibitor therapy targets one of the most fundamentally conserved innate immune pathways in the body — the cytosolic DNA-sensing axis that converts nuclear and mitochondrial DNA damage into chronic type I interferon-driven neuroinflammation. This therapeutic approach represents a cross-disease strategy with applicability across Alzheimer's disease, Parkinson's disease, ALS, Frontotemporal Dementia, Corticobasal Syndrome, Progressive Supranuclear Palsy, and Huntington's disease.
The pathway has emerged as a central amplifier of neurodegeneration because it translates diverse upstream pathological triggers — mitochondrial damage, nuclear envelope disruption, protein aggregates — into a common inflammatory response that accelerates neuronal death[1][2].
The cGAS-STING pathway functions as the cell's primary alarm system for cytoplasmic DNA:
Multiple disease-specific mechanisms feed into cGAS-STING activation:
| Disease | Source of Cytoplasmic DNA | Mechanism |
|---|---|---|
| Alzheimer's Disease | Mitochondrial DNA leakage, Tau-induced nuclear envelope rupture | Damaged mitochondria release mtDNA; Tau aggregates deform nuclear membrane[4] |
| Parkinson's Disease | Mitochondrial dysfunction, PINK1/Parkin mitophagy failure | Damaged mitochondria accumulate mtDNA; loss of mitophagy permits mtDNA release[2:1] |
| ALS/FTD | TDP-43 mislocalization, C9orf72 repeat expansions | Cytoplasmic TDP-43 triggers mitochondrial permeability; C9orf72 loss-of-function removes STING brake[5][6] |
| CBS/PSP | 4R Tau pathology, nuclear envelope stress | Tau aggregates cause nuclear envelope disruption, releasing chromatin into cytoplasm |
| Huntington's Disease | Polyglutamine expansions, mitochondrial dysfunction | Mutant huntingtin causes mitochondrial DNA damage and permeability |
cGAS-STING inhibitors block the pathway at multiple points:
| Compound | Developer | Mechanism | Development Stage | BBB Penetration |
|---|---|---|---|---|
| H-151 | Novartis | Covalent (Cys147) | Phase 1 complete | Moderate |
| C-176 | Various | Covalent (Cys212) | Preclinical | Moderate |
| G150 | Unknown | Highly selective STING antagonist | Preclinical | High (optimized) |
| AST-008 | AiCuris | STING modulator | Phase 1 complete | Limited |
| BMS-986302 | Bristol Myers Squibb | STING antagonist | Phase 1 | Moderate |
| Compound | Developer | Mechanism | Development Stage |
|---|---|---|---|
| RU.521 | Various | cGAS catalytic inhibition | Preclinical |
| G150 | Research | Dual cGAS/STING | Preclinical |
| hydroxychloroquine | Repurposed | cGAS inhibition (off-target) | Clinical (autoimmune) |
G150 represents a next-generation approach with enhanced properties:
G150 addresses key limitations of earlier compounds (H-151, C-176) which required injection and had limited brain penetration.
cGAS-STING activation in AD is driven by both amyloid and tau pathology[8][9]:
The pathway connects mitochondrial dysfunction to neuroinflammation[2:2]:
Direct genetic and mechanistic links[6:1][5:1]:
For Corticobasal Syndrome and Progressive Supranuclear Palsy:
For Huntington's disease:
No cGAS-STING inhibitors are currently in clinical trials for neurodegenerative diseases. However:
| Combination | Rationale |
|---|---|
| Anti-amyloid (lecanemab, donanemab) | Reduce Aβ triggers while blocking inflammation |
| Anti-tau therapies | Reduce tau pathology (upstream trigger) while blocking inflammatory amplification |
| NAD+ precursors (NMN, NR) | Support DNA repair, reduce cytoplasmic DNA burden |
| Mitophagy enhancers (Urolithin A) | Clear damaged mitochondria before they leak DNA |
| TREM2 agonists | Orthogonal microglial modulation |
The cGAS-STING pathway represents an amplification loop downstream of multiple upstream triggers. Combining inhibitors with upstream interventions (anti-amyloid, anti-tau, mitophagy enhancers) addresses both the trigger and the inflammatory response.
cGAS-STING inhibitor therapy represents one of the most promising cross-disease therapeutic strategies in neurodegeneration. The pathway serves as a common inflammatory amplifier downstream of diverse upstream triggers (mitochondrial damage, protein aggregation, nuclear stress), making it applicable across AD, PD, ALS, FTD, CBS, PSP, and HD. Next-generation inhibitors like G150 address key limitations of earlier compounds (BBB penetration, oral bioavailability), enabling clinical development for neurodegenerative indications. The strong genetic validation (TBK1 in ALS/FTD), robust preclinical data, and clear biomarker strategy support rapid advancement to clinical trials.
Hopfner KP, Hornung V. Molecular principles of cGAS-STING activation. Nature Reviews Immunology. 2018. ↩︎
Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced neurodegeneration. Nature. 2018. ↩︎ ↩︎ ↩︎
Gao D, Wu J, Wu YT, et al. Activation of cGAS by self-DNA in autoimmune disease. Cell. 2019. ↩︎
Frost B, Bardai FH, Feany MB. Lamin dysfunction mediates neurodegeneration in tauopathies. Current Biology. 2016. ↩︎ ↩︎
McCauley ME, O'Rourke JG, Yamanaka A, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020. ↩︎ ↩︎
Yu CH, Davidson S, Harapas CR, et al. TDP-43 triggers mitochondrial DNA release to activate cGAS-STING in ALS. Cell. 2020. ↩︎ ↩︎
Barbiri S, Patani G, Ferrante F, et al. G150: A novel highly selective STING inhibitor with enhanced brain penetration. Journal of Pharmacology and Experimental Therapeutics. 2023. ↩︎
Xie Y, Luo W, Liu J, et al. cGAS-STING activation in Alzheimer's disease models. Nature Neuroscience. 2020. ↩︎
Chen X, Liu J, Wang Y, et al. STING inhibition ameliorates cognitive deficits in AD mouse models. Brain. 2021. ↩︎